Preventive Efficacy and Safety of Yiqi-Wenjing-Fang Granules on Oxaliplatin-Induced Peripheral Neuropathy: A Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

<div>Schedule of enrollment, allocation, intervention, and assessment. <i>Note</i>. Subjects will complete the EORTC QLQ-CIPN20 questionnaire for 4 consecutive times during cycle 1 (refer to 2.8). EORTC QLQ-CIPN20: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale; NCI-CTCAE 5.0: National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer’s Core Quality of Life Questionnaire; RECIST 1.1: Response Evaluation Criteria in Solid Tumors Version 1.1.</div>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: Preventive Efficacy and Safety of Yiqi-Wenjing-Fang Granules on Oxaliplatin-Induced Peripheral Neuropathy: A Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial 

Figure 2 | Preventive Efficacy and Safety of Yiqi-Wenjing-Fang Granules on Oxaliplatin-Induced Peripheral Neuropathy: A Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial 